286 related articles for article (PubMed ID: 32829249)
21. Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs.
Cyrus K; Wehenkel M; Choi EY; Lee H; Swanson H; Kim KB
ChemMedChem; 2010 Jul; 5(7):979-85. PubMed ID: 20512796
[TBL] [Abstract][Full Text] [Related]
22. In silico screening for ERα down modulators identifies thioridazine as an anti-proliferative agent in primary, 4OH-tamoxifen-resistant and Y537S ERα-expressing breast cancer cells.
Busonero C; Leone S; Bianchi F; Acconcia F
Cell Oncol (Dordr); 2018 Dec; 41(6):677-686. PubMed ID: 30182339
[TBL] [Abstract][Full Text] [Related]
23. Discovery of estrogen receptor α targeting caged hypoxia-responsive PROTACs with an inherent bicyclic skeleton for breast cancer treatment.
Xie B; Xu B; Xin L; Wei Y; Guo X; Dong C
Bioorg Chem; 2023 Aug; 137():106590. PubMed ID: 37163809
[TBL] [Abstract][Full Text] [Related]
24. Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine.
Sui M; Jiang D; Hinsch C; Fan W
Breast Cancer Res Treat; 2010 Jun; 121(2):335-45. PubMed ID: 19626437
[TBL] [Abstract][Full Text] [Related]
25. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
Busonero C; Leone S; Bartoloni S; Acconcia F
Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
[TBL] [Abstract][Full Text] [Related]
26. Aurora-A mitotic kinase induces endocrine resistance through down-regulation of ERα expression in initially ERα+ breast cancer cells.
Opyrchal M; Salisbury JL; Zhang S; McCubrey J; Hawse J; Goetz MP; Lomberk GA; Haddad T; Degnim A; Lange C; Ingle JN; Galanis E; D'Assoro AB
PLoS One; 2014; 9(5):e96995. PubMed ID: 24816249
[TBL] [Abstract][Full Text] [Related]
27. Development of cell-permeable peptide-based PROTACs targeting estrogen receptor α.
Dai Y; Yue N; Gong J; Liu C; Li Q; Zhou J; Huang W; Qian H
Eur J Med Chem; 2020 Feb; 187():111967. PubMed ID: 31865016
[TBL] [Abstract][Full Text] [Related]
28. Next-Generation ERα Inhibitors for Endocrine-Resistant ER+ Breast Cancer.
Fanning SW; Greene GL
Endocrinology; 2019 Apr; 160(4):759-769. PubMed ID: 30753408
[TBL] [Abstract][Full Text] [Related]
29. The estrogen receptor alpha nuclear localization sequence is critical for fulvestrant-induced degradation of the receptor.
Casa AJ; Hochbaum D; Sreekumar S; Oesterreich S; Lee AV
Mol Cell Endocrinol; 2015 Nov; 415():76-86. PubMed ID: 26272024
[TBL] [Abstract][Full Text] [Related]
30. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
[TBL] [Abstract][Full Text] [Related]
31. A functional drug re-purposing screening identifies carfilzomib as a drug preventing 17β-estradiol: ERα signaling and cell proliferation in breast cancer cells.
Busonero C; Leone S; Klemm C; Acconcia F
Mol Cell Endocrinol; 2018 Jan; 460():229-237. PubMed ID: 28760601
[TBL] [Abstract][Full Text] [Related]
32. PROTACs: A novel strategy for cancer therapy.
Liu J; Ma J; Liu Y; Xia J; Li Y; Wang ZP; Wei W
Semin Cancer Biol; 2020 Dec; 67(Pt 2):171-179. PubMed ID: 32058059
[TBL] [Abstract][Full Text] [Related]
33. Structural Optimization of Decoy Oligonucleotide-Based PROTAC That Degrades the Estrogen Receptor.
Naganuma M; Ohoka N; Tsuji G; Inoue T; Naito M; Demizu Y
Bioconjug Chem; 2023 Oct; 34(10):1780-1788. PubMed ID: 37736001
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor α attenuates therapeutic efficacy of paclitaxel on breast xenograft tumors.
Chang J; Sui M; Fan W
Breast Cancer Res Treat; 2012 Aug; 134(3):969-80. PubMed ID: 22374518
[TBL] [Abstract][Full Text] [Related]
35. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
[TBL] [Abstract][Full Text] [Related]
36. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
37. COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR.
Lu R; Hu X; Zhou J; Sun J; Zhu AZ; Xu X; Zheng H; Gao X; Wang X; Jin H; Zhu P; Guo L
Nat Commun; 2016 Jul; 7():12044. PubMed ID: 27375289
[TBL] [Abstract][Full Text] [Related]
38. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
[TBL] [Abstract][Full Text] [Related]
39. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
40. New steps on an old path: Novel estrogen receptor inhibitors in breast cancer.
Pagliuca M; Donato M; D'Amato AL; Rosanova M; Russo AOM; Scafetta R; De Angelis C; Trivedi MV; André F; Arpino G; Del Mastro L; De Laurentiis M; Puglisi F; Giuliano M
Crit Rev Oncol Hematol; 2022 Dec; 180():103861. PubMed ID: 36374739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
